Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Detaylı Bibliyografya
Asıl Yazarlar:	Preiss, D, Herrington, W, Haynes, R
Materyal Türü:	Conference item
Dil:	English
Baskı/Yayın Bilgisi:	American Heart Association 2022

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Yazar:: Mayne, K, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Yazar:: Mayne, KM, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
Yazar:: Nangaku, M, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Yazar:: Staplin, N, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
Yazar:: Takashi Kadowaki, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Empagliflozin in patients with chronic kidney disease
Yazar:: Herrington, WG, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial
Yazar:: Roland Schmitt, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
Yazar:: Ayodele Odutayo, MD, DPhil, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
Yazar:: Mayne, K, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
Yazar:: Coleman, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
Yazar:: David Fitchett, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Long-term effects of empagliflozin in patients with chronic kidney disease
Yazar:: Herrington, WG, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
Yazar:: Samy Hadjadj, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
Yazar:: Subodh Verma, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome
Yazar:: Mahmoud Elrouby, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
Yazar:: Judge, PK, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Yazar:: Hundertmark, MJ, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Yazar:: Moritz J. Hundertmark, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Yazar:: Coleman, RL, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
Yazar:: Hilmi Alnsasra, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
Yazar:: Antonio Ceriello, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
Yazar:: Pierpaolo Pellicori, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study
Yazar:: Sergio Iannazzo, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Yazar:: David Fitchett, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands
Yazar:: Bart Slob, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands.
Yazar:: Bart Slob, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Yazar:: João Pedro Ferreira, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
Yazar:: Zhu, D, ve diğerleri
Baskı/Yayın Bilgisi: (2025)

Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial
Yazar:: Shinya Fujiki, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial
Yazar:: Hundertmark, MJ, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Kidney disease trials for the 21st century: innovations in design and conduct
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Yazar:: Sepehr Gohari, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Yazar:: Silvie Hojná, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
Yazar:: Zhu, D, ve diğerleri
Baskı/Yayın Bilgisi: (2025)

Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/linagliptin in heart failure and diabetes
Yazar:: Sharvil S Gadve, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Chronic kidney disease, heart failure and neprilysin inhibition
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
Yazar:: Schlackow, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Benzer Materyaller

Benzer Materyaller